PhD Scientific Days 2017

Poster Presentation: Oncology

P45: The potential predictive role of increased mTORC2 activity in brain metastasis formation of pulmonary adenocarcinomas

Előadó neve

Dr. Krencz, Ildikó

Előadó munkahelye

1st Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest

Előadó telefonszáma

06203764491

Előadó e-mail címe

krencz.ildiko@gmail.com

Az előadás címe

The potential predictive role of increased mTORC2 activity in brain metastasis formation of pulmonary adenocarcinomas

Szerző(k) neve és munkahelye

Ildikó Krencz1, Anna Sebestyén1,2, Zoltán Hujber1, Gábor Petővári1, Noémi Nagy1, Titanilla Dankó1, Judit Moldvay3, Judit Pápay1
1 1st Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest
2 Tumor Progression Research Group Joint Research Organization of Hungarian Academy of Sciences and Semmelweis University, Budapest
3 Department of Tumor Biology, National Korányi Institute of TB and Pulmonology, Budapest

Szekció

Poster Presentation: Oncology

Data of the presenter

Doctoral School: Doctoral School of Pathological Sciences
Program: Experimental Oncology
Supervisor: Dr. Judit Pápay
E-mail: krencz.ildiko@gmail.com

Text of the abstract

Brain metastases are common complications of pulmonary adenocarcinomas and have a poor prognosis despite the use of multimodal therapies. It has been described that dysregulated activity of mammalian target of rapamycin (mTOR) pathway can promote the metastatic potential of various tumors, however, their role and predictive value in brain metastases is unknown. The aim of this study was to analyze the expressions of mTORC1 and mTORC2 related proteins in primary adenocarcinomas of the lung (ADCs) with and without brain metastases.
Pulmonary ADCs with known brain metastases (n=24) and no information about metastasis formation (n=41) were studied. Clinical data were obtained from medical records; the median follow up was 2.5 years. The expression of mTOR related proteins (mTORC1: p-mTOR, p-S6; mTORC2: p-mTOR, Rictor) were studied using immunohistochemistry on tissue microarrays. Mann-Whitney U-test was used for the comparison of the expressions of the mTOR activity markers between adenocarcinomas with and without brain metastases.
Increased expressions of p-mTOR, p-S6 and Rictor were observed in 71%, 58% and 71% of the metastasizing adenocarcinomas and in 41%, 46% and 44% of the adenocarcinomas without brain metastases. The expressions of p-mTOR and Rictor were significantly higher in adenocarcinomas with brain metastases compared to non-metastasizing tumors (p=0.014 and p=0.003, respectively). The expression of p-S6, however, does not differ significantly between metastasizing and non- metastasizing pulmonary adenocarcinomas (p=0.356).
The increased expression of p-mTOR and Rictor in brain-metastasizing adenocarcinomas of the lung draw attention to the potential predictive role of high mTORC2 activity in metastasis formation and suggest to determine mTORC1/C2 activity profile which may aid in a more accurate selection of lung cancer patients with a greater likelihood to benefit from mTORC1/C2 inhibitor therapy.

Supported by MTA Bolyai Grant (AS), ÚNKP-16-3 (NN) and NTP-NFTÖ-16 (ZH).

Azonosító

P45

Kind

Szabad

Előadás fájl jóváhagyás

nem rendelkezett róla

Előadó

1307

Authors (legacy)

Ildikó Krencz1, Anna Sebestyén1,2, Zoltán Hujber1, Gábor Petővári1, Noémi Nagy1, Titanilla Dankó1, Judit Moldvay3, Judit Pápay1
1 1st Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest
2 Tumor Progression Research Group Joint Research Organization of Hungarian Academy of Sciences and Semmelweis University, Budapest
3 Department of Tumor Biology, National Korányi Institute of TB and Pulmonology, Budapest